Cell therapy is therapy in which cellular material is injected into a patient; this generally means intact, living cells. For example, T cells capable of fighting cancer cells via cell-mediated immunity may be injected in the course of immunotherapy.
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: December 14, 2017TIME: 05:00am PST, 08:00am EST, 2:00pm CETvon Willebrand Disease (vWD) is one of the most common congenital bleeding disorders, affecting ~1%* of the world’...
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
Derivation of many different cell types from human pluripotent stem cells (embryonic stem cells or HESCs and induced pluripotent stem cells or hiPS cells) is an area of growing interest both ...
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...
DATE: October 26, 2017TIME: 12:00 PM PDTThis presentation will focus on recent advances in cellular therapy—from mesenchymal stromal cells (MSCs) to tumor-specific T-cells. More s...
DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
The detection of CTCs has been used as useful biomarkers in prognosis and monitoring therapeutic response of patients with metastatic cancer. However, during the course of cancer therapy, CTC...
Colorectal cancer (CRC) is the third most common cancer among Americans, and the second deadliest. Its pathogenesis results from an interplay between environmental factors that influence biol...
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
The “R2G2” (B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd) knockout mouse is the latest advancement to provide an alternative option in the highly immunodeficient mouse model category for...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: October 10, 2017TIME: 9:00AM PDTPatient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line...
Stem cells can self-renew and differentiate into multiple different cell types. Engineering of stem cells has enabled new methods to study development and organogenesis in humans as well as d...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
Checkpoint blockade therapy for cancer has had tremendous impact on clinical outcomes, yet only a subset of patients respond. Recent studies show that response to checkpoint blockade does not...
DATE: September 21, 2017TIME: 8:00AM PSTBoard-certified hematologist-oncologist Ola Landgren, MD, PhD, will review how vague symptoms (fatigue, bone pain, back pain) are linked to...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: December 14, 2017TIME: 05:00am PST, 08:00am EST, 2:00pm CETvon Willebrand Disease (vWD) is one of the most common congenital bleeding disorders, affecting ~1%* of the world’...
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
Derivation of many different cell types from human pluripotent stem cells (embryonic stem cells or HESCs and induced pluripotent stem cells or hiPS cells) is an area of growing interest both ...
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...
DATE: October 26, 2017TIME: 12:00 PM PDTThis presentation will focus on recent advances in cellular therapy—from mesenchymal stromal cells (MSCs) to tumor-specific T-cells. More s...
DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
The detection of CTCs has been used as useful biomarkers in prognosis and monitoring therapeutic response of patients with metastatic cancer. However, during the course of cancer therapy, CTC...
Colorectal cancer (CRC) is the third most common cancer among Americans, and the second deadliest. Its pathogenesis results from an interplay between environmental factors that influence biol...
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
The “R2G2” (B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd) knockout mouse is the latest advancement to provide an alternative option in the highly immunodeficient mouse model category for...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: October 10, 2017TIME: 9:00AM PDTPatient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line...
Stem cells can self-renew and differentiate into multiple different cell types. Engineering of stem cells has enabled new methods to study development and organogenesis in humans as well as d...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
Checkpoint blockade therapy for cancer has had tremendous impact on clinical outcomes, yet only a subset of patients respond. Recent studies show that response to checkpoint blockade does not...
DATE: September 21, 2017TIME: 8:00AM PSTBoard-certified hematologist-oncologist Ola Landgren, MD, PhD, will review how vague symptoms (fatigue, bone pain, back pain) are linked to...
Follow
